Although clinical risk factors such as age, WBC at presentation, presence of CNS disease [11], and genetic abnormalities such as RAS and PTEN mutations [40] have prognostic significance, MRD remains the single most important prognostic indicator in pediatric and young adult T-ALL as demonstrated in multicenter cooperative group trials [83,84]. This evidence concerns the gene PTEN and acute lymphoblastic leukemia.